Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;8(Suppl 6):S618-S620.
doi: 10.21037/tcr.2019.06.28.

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

Alfonso Fiorelli  1 , Fabiana Vitiello  2 , Floriana Morgillo  3 , Mario Santagata  4 , Chiara Spuntarelli  4 , Marina Di Domenico  5 , Mario Santini  1 , Andrea Bianco  6
Affiliations
Editorial

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

Alfonso Fiorelli et al. Transl Cancer Res. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.06.28). The authors have no conflicts of interest to declare.

Comment on

References

    1. Fiorelli A, Sagan D, Mackiewicz L, et al. Incidence, Risk Factors, and Analysis of Survival of Unexpected N2 Disease in Stage I Non-Small Cell Lung Cancer. Thorac Cardiovasc Surg 2015;63:558-67. 10.1055/s-0034-1399764 - DOI - PubMed
    1. Fiorelli A, Santini M. In lung cancer patients were a malignant pleural effusion is found at operation could resection ever still be justified? Interact Cardiovasc Thorac Surg 2013;17:407-12. 10.1093/icvts/ivt153 - DOI - PMC - PubMed
    1. Fiorelli A, Perrotta F, Mollica M, et al. Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report. J Cardiothorac Surg 2019;14:50. 10.1186/s13019-019-0862-6 - DOI - PMC - PubMed
    1. Bianco A, Malapelle U, Rocco D, et al. Targeting immune checkpoints in non small cell lung cancer. Curr Opin Pharmacol 2018;40:46-50. 10.1016/j.coph.2018.02.006 - DOI - PubMed
    1. Bianco A, Campbell SFM. Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? Transl Cancer Res 2019;8:S103-5. 10.21037/tcr.2018.11.06 - DOI - PMC - PubMed